Hepatic failure steroid

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential of ibrutinib and its further development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products or new indications; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

  1. Abdominal Pain Slideshow Pictures
  2. Caffeine Quiz: Test Your Medical IQ
  3. Healthy Dieting Myths and Facts Slideshow
IN THIS ARTICLE
  • What Are Gallstones?
  • Gallstones Causes
  • Gallstones and Diet
  • Gallstones Symptoms
  • When to Seek Medical Care for Gallstones
  • Gallstones Diagnosis
  • Gallstones Home Remedies
  • Gallstones Treatment
  • Gallstone Surgery (Cholecystectomy)
  • Gallstones Follow-up
  • Gallstones Prevention Diet
  • Gallstones Prognosis
  • Read more on Gallstones from Healthwise
  • Gallstones Topic Guide
Gallstones Symptoms

Drug-induced and indeterminate acute liver failure (ALF) might be due to an autoimmune-like hepatitis that is responsive to corticosteroid therapy. The aim of this study was to evaluate whether corticosteroids improve survival in fulminant autoimmune hepatitis, drug-induced, or indeterminate ALF, and whether this benefit varies according to the severity of illness. We conducted a retrospective analysis of autoimmune, indeterminate, and drug-induced ALF patients in the Acute Liver Failure Study Group from 1998-2007. The primary endpoints were overall and spontaneous survival (SS, survival without transplant). In all, 361 ALF patients were studied, 66 with autoimmune (25 steroids, 41 no steroids), 164 with indeterminate (21 steroids, 143 no steroids), and 131 with drug-induced (16 steroids, 115 no steroids) ALF. Steroid use was not associated with improved overall survival (61% versus 66%, P  = ), nor with improved survival in any diagnosis category. Steroid use was associated with diminished survival in certain subgroups of patients, including those with the highest quartile of the Model for Endstage Liver Disease (MELD) (>40, survival 30% versus 57%, P  = ). In multivariate analysis controlling for steroid use and diagnosis, age (odds ratio [OR] per decade), coma grade (OR grade 2, grade 3, grade 4), MELD (OR ), and pH <  (OR ) were significantly associated with mortality. Although steroid use was associated with a marginal benefit in SS overall (35% versus 23%, P  = ), this benefit did not persistent in multivariate analysis; mechanical ventilation (OR ), MELD (OR ), and alanine aminotransferase () were the only significant predictors of SS. Conclusion : Corticosteroids did not improve overall survival or SS in drug-induced, indeterminate, or autoimmune ALF and were associated with lower survival in patients with the highest MELD scores. (H epatology 2014;59:612–621)

Hepatic failure steroid

hepatic failure steroid

Media:

hepatic failure steroidhepatic failure steroidhepatic failure steroidhepatic failure steroidhepatic failure steroid

http://buy-steroids.org